

# Christoph WÃ¼rnschimmel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1385078/publications.pdf>

Version: 2024-02-01

92  
papers

657  
citations

840776

11  
h-index

888059

17  
g-index

101  
all docs

101  
docs citations

101  
times ranked

436  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Randomized Trial Comparing Titanium Clips to Bipolar Coagulation in Sealing Lymphatic Vessels During Pelvic Lymph Node Dissection at the Time of Robot-assisted Radical Prostatectomy. <i>European Urology</i> , 2017, 71, 155-158.	1.9	55
2	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 399-408.	3.1	29
3	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 139-148.	3.9	28
4	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. <i>International Journal of Urology</i> , 2021, 28, 862-869.	1.0	22
5	Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. <i>Journal of Urology</i> , 2021, 205, 1663-1670.	0.4	22
6	Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 375-384.	0.4	18
7	Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 830.e17-830.e26.	1.6	17
8	Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 659135.	2.8	16
9	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , 2021, 32, 627-634.	1.8	15
10	Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. <i>Prostate</i> , 2021, 81, 874-881.	2.3	15
11	Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort. <i>Prostate</i> , 2021, 81, 849-856.	2.3	14
12	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. <i>Prostate</i> , 2021, 81, 339-346.	2.3	13
13	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. <i>Diagnostics</i> , 2021, 11, 882.	2.6	13
14	Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy. <i>International Urology and Nephrology</i> , 2021, 53, 1297-1303.	1.4	12
15	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. <i>European Urology Focus</i> , 2022, 8, 710-717.	3.1	12
16	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 69-79.	0.4	12
17	PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. <i>EJNMMI Research</i> , 2021, 11, 76.	2.5	12
18	Martini-Klinik experience of prostate cancer surgery during the early phase of the COVID-19 pandemic. <i>BJU International</i> , 2020, 126, 252-255.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Standardized and Simplified Robot-assisted Superextended Pelvic Lymph Node Dissection for Prostate Cancer: The Monoblock Technique. <i>European Urology</i> , 2020, 78, 424-431.	1.9	11
20	Nonâ€cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. <i>Prostate</i> , 2021, 81, 728-735.	2.3	11
21	Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. <i>European Urology Focus</i> , 2022, 8, 1133-1140.	3.1	11
22	Immunohistochemistry for Prostate Biopsyâ€”Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. <i>Current Oncology</i> , 2021, 28, 2123-2133.	2.2	10
23	Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. <i>International Urology and Nephrology</i> , 2022, 54, 1521-1527.	1.4	10
24	The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 255-258.	3.1	9
25	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , 2021, 39, 3781-3787.	2.2	9
26	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2022, 40, 103-110.	2.2	9
27	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aNOMO Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2022, 8, 191-199.	3.1	8
28	Impact of comorbidities on acute kidney injury and renal function impairment after partial and radical tumor nephrectomy. <i>Scandinavian Journal of Urology</i> , 2021, 55, 377-382.	1.0	8
29	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e255-e263.	1.9	8
30	Improvement in overall and cancerâ€cspecific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. <i>Prostate</i> , 2021, 81, 1374-1381.	2.3	8
31	Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. <i>Cancer Epidemiology</i> , 2021, 74, 101994.	1.9	8
32	Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 165.e9-165.e15.	1.6	8
33	Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. <i>World Journal of Urology</i> , 2022, 40, 1481-1488.	2.2	8
34	Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 135-143.	1.9	7
35	The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 57.e15-57.e23.	1.6	7
36	Cystatin C predicts renal function impairment after partial or radical tumor nephrectomy. <i>International Urology and Nephrology</i> , 2021, 53, 2041-2049.	1.4	7

#	ARTICLE	IF	CITATIONS
37	External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 17-24.	1.0	7
38	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 778858.	2.8	7
39	Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. <i>Prostate</i> , 2022, 82, 740-750.	2.3	7
40	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e11-785.e17.	1.6	6
41	The role of nephrectomy in metastatic renal cell carcinoma in the immuno-oncology era. <i>BJU International</i> , 2021, 128, 438-439.	2.5	6
42	Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data. <i>Prostate</i> , 2021, 81, 785-793.	2.3	6
43	PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 7.e1-7.e8.	1.6	6
44	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e7-788.e13.	1.6	6
45	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207400.	2.0	5
46	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1707-1713.	2.2	5
47	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 789.e9-789.e17.	1.6	5
48	The effect of primary urological cancers on survival in men with secondary prostate cancer. <i>Prostate</i> , 2021, 81, 1149-1158.	2.3	5
49	Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103534.	4.4	5
50	MRI as a screening tool for prostate cancer: current evidence and future challenges. <i>World Journal of Urology</i> , 2023, 41, 921-928.	2.2	5
51	Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e380-e389.	1.9	5
52	Medial patellofemoral ligament (MPFL) reconstruction in combination with a modified grammont technique leads to favorable mid-term results in adolescents with recurrent patellofemoral dislocations. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2018, 26, 705-709.	4.2	4
53	Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings. <i>Urology</i> , 2020, 136, 127-132.	1.0	4
54	Re: Paolo Afonso de Carvalho, Joãõ A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. <i>Eur Urol</i> 2020;77:628-35. <i>European Urology</i> , 2021, 79, e44-e46.	1.9	4

#	ARTICLE	IF	CITATIONS
55	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , 2022, 33, 25-35.	1.8	4
56	Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. <i>European Urology</i> , 2021, 80, 400-404.	1.9	4
57	Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. <i>Prostate</i> , 2022, 82, 676-686.	2.3	4
58	Accuracy of standardized 12â€œcore template biopsies versus nonâ€œstandardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen. <i>Prostate</i> , 2018, 78, 365-369.	2.3	3
59	Orphaned Side-effects After Robot-assisted Radical Prostatectomy: Is the Retzius-sparing Approach Superior to the Standard Approach or Are the Data Just Not Mature Enough?. <i>European Urology Open Science</i> , 2021, 23, 34-35.	0.4	3
60	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. <i>World Journal of Urology</i> , 2021, 39, 4127-4133.	2.2	3
61	Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 215-228.	0.7	3
62	Stage and cancerâ€œspecific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American populationâ€œbased study. <i>International Journal of Urology</i> , 2021, 28, 1247-1252.	1.0	3
63	Comparison of Complication Rates with Antibiotic Prophylaxis with Cefpodoxime Versus Fluoroquinolones After Transrectal Prostate Biopsy. <i>European Urology Focus</i> , 2021, 7, 980-986.	3.1	3
64	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. <i>Prostate</i> , 2022, 82, 78-85.	2.3	3
65	Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 96-96.	1.0	3
66	Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer. <i>Prostate</i> , 2022, 82, 254-259.	2.3	3
67	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 708-717.	3.2	3
68	Presence of biopsy Gleason pattern 5â€œ+â€œ3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. <i>Prostate</i> , 2021, 81, 778-784.	2.3	2
69	Significant reduction of lymphoceles after radical prostatectomy and pelvic lymph node dissection. <i>BJU International</i> , 2021, 128, 728-733.	2.5	2
70	Assessment of the optimal number of positive biopsy cores to discriminate between cancerâ€œspecific mortality in highâ€œrisk versus very highâ€œrisk prostate cancer patients. <i>Prostate</i> , 2021, 81, 1055-1063.	2.3	2
71	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 155, 245-255.	2.8	2
72	Radical cystectomy vs radiotherapy in urothelial bladder cancer in elderly and very elderly patients. <i>Clinical Genitourinary Cancer</i> , 2021, , .	1.9	2

#	ARTICLE	IF	CITATIONS
73	Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. <i>Prostate</i> , 2022, 82, 120-131.	2.3	2
74	Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. <i>International Urology and Nephrology</i> , 2022, 54, 89-95.	1.4	2
75	Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.. <i>Prostate</i> , 2022, 82, 399-400.	2.3	2
76	Catheterization Does Not Improve Course of Disease in Female Patients with Acute Cystitis or Pyelonephritis: Retrospective Analysis of 300 In-Hospital Treated Patients. <i>Urologia Internationalis</i> , 2021, 105, 1-9.	1.3	1
77	MP50-14 THE IMPACT OF RACE/ETHNICITY ON UPSTAGING AND/OR UPGRADING RATES AMONG INTERMEDIATE RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2021, 206, .	0.4	1
78	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. <i>Cancer Causes and Control</i> , 2022, 33, 769-777.	1.8	1
79	Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy. <i>Frontiers in Surgery</i> , 2021, 8, 759070.	1.4	1
80	Reply to the letter to the editor: RE: Wenzel M, et al. The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. <i>The Prostate</i> . 2021;18. <i>Prostate</i> , 2021, 81, 795-795.	2.3	0
81	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 79-79.	0.4	0
82	MP43-08 INCREASING RATES OF NCCN HIGH AND VERY HIGH-RISK PROSTATE CANCER VS. NUMBER OF PROSTATE BIOPSY CORES. <i>Journal of Urology</i> , 2021, 206, .	0.4	0
83	MP48-19 STAGE AND CANCER SPECIFIC MORTALITY DIFFERS WITHIN SPECIFIC ASIAN ETHNIC GROUPS IN UPPER TRACT UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2021, 206, .	0.4	0
84	Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant. <i>Prostate</i> , 2021, 81, 1294-1302.	2.3	0
85	The Impact of Preoperative Double-J Stent on Perioperative Complications, Recurrence, and Quality of Life in Adult Patients Undergoing Pyeloplasty. <i>Urologia Internationalis</i> , 2021, , 1-8.	1.3	0
86	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754996.	2.8	0
87	MP03-10 LIFE EXPECTANCY IN METASTATIC UROTHELIAL BLADDER CANCER PATIENTS ACCORDING TO RACE/ETHNICITY. <i>Journal of Urology</i> , 2022, 207, .	0.4	0
88	PD42-07 RADICAL VS PARTIAL CYSTECTOMY FOR URACHAL CARCINOMA: A POPULATION-BASED ANALYSIS. <i>Journal of Urology</i> , 2022, 207, .	0.4	0
89	MP15-16 VALIDATION OF EAU RECOMMENDATION FOR SALVAGE RADICAL PROSTATECTOMY CANDIDATES. <i>Journal of Urology</i> , 2022, 207, .	0.4	0
90	PD60-04 SURVIVAL AFTER RADICAL PROSTATECTOMY VS. RADIATION THERAPY IN CLINICAL NODE-POSITIVE PROSTATE CANCER. <i>Journal of Urology</i> , 2022, 207, .	0.4	0

#	ARTICLE	IF	CITATIONS
91	MP15-20â€fSURVIVAL AFTER RADICAL PROSTATECTOMY VS. RADIATION THERAPY IN DUCTAL CARCINOMA OF THE PROSTATE. Journal of Urology, 2022, 207, .	0.4	0
92	MP53-13â€fTRANSITION OF PROSTATE CANCER PRIMARY DIAGNOSTICS: TAKEOVER OF MRI-GUIDED TARGETED- VERSUS SYSTEMATIC BIOPSY. Journal of Urology, 2022, 207, .	0.4	0